MUC16 and cirrhosis of liver: The clinical usefulness of CA125 in diagnosis of pancreatic cancer is further limited, because 64% of patients with liver cirrhosis, 23% of patients with hepatitis, 25%–38% of patients with pancreatitis, and 35% of patients with jaundice also have increased levels of CA125 [8,55] (Figure 1).